Description
Seeking people aged up to 21 years for a study of decreasing the length of chemotherapy treatment for people with low risk rhabdomyosarcoma and increasing the length of chemotherapy treatment for people with high risk rhabrhabdomyosarcoma.
Overview
Participants in this study whose soft tissue tumor due to rhabdomyosarcoma has DNA mutations will get chemotherapy treatment for up to 11 months and those whose tumors do not have DNA mutations will get chemotherapy for up to 6 months.
What we're hoping for
We are studying whether it is better to increase or decrease the length of chemotherapy treatment based on if the soft tissue tumor due to rhabdomyosarcoma has DNA mutations.
Additional Information
ClinicalTrials.gov Identifier: NCT05304585